Brief: ADC Therapeutics Announces First Patient Dosed In Phase 2 Clinical Trial Of Zynlonta® (Loncastuximab Tesirine-Lpyl) In Combination With Rituximab In First-Line Diffuse Large B-Cell Lymphoma
20/07/2022 12:59
July 20 (Reuters) - ADC Therapeutics SA ADCT.N :
* ADC THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 2
CLINICAL TRIAL OF ZYNLONTA® (LONCASTUXIMAB TESIRINE-LPYL) IN
COMBINATION WITH RITUXIMAB IN FIRST-LINE DIFFUSE LARGE B-CELL
LYMPHOMA
Source text for Eikon: ID:nBw2Dr4dZa
Further company coverage: ADCT.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adc Therapeutics
See all newsBrief: Adc Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements
ADC Therapeutics SA reports results for the quarter ended June 30 - Earnings Summary
ADC Therapeutics Q2 loss narrows; cuts 17% workforce
ADC Therapeutics SA expected to post a loss of 21 cents a share - Earnings Preview
ADC Therapeutics SA expected to post a loss of 21 cents a share - Earnings Preview